Cowen Remains Bullish on Gilead Sciences (GILD) Following Data Release
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Biotechs Pressured Following Clinton Tweet (IBB)
September 21, 2015 12:35 PM EDTBiotech stocks are getting hit on Monday following a post to Twitter by presidential candidate Hillary Clinton.
Gilead Sciences (GILD) Announces Positive Update on Four Sofosbuvir Combo Phase 3s in Certain HCV
September 21, 2015 8:32 AM EDTGilead Sciences (NASDAQ: GILD) announced topline results from four international Phase 3 clinical studies (ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4) evaluating a once-daily, fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF) with velpatasvir (VEL), an investigational pangenotypic NS5A inhibitor, for the treatment of genotype 1-6 chronic hepatitis C virus (HCV) infection.
In the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies, 1,035 patients with genotype 1-6 HCV infection received 12 weeks of SOF/VEL. Among these patients, 21 percent had compensated cirrhosis and 28 percent had failed prior treatments. The ASTRAL-4 study randomized 267 patients with decompensated... More
UPDATE: Bristol-Myers Squibb (BMY) Ticks Higher on Unconfirmed Chatter
September 18, 2015 1:50 PM EDT(Updated - September 18, 2015 2:10 PM EDT)
Bristol-Myers Squibb (NYSE: BMY) ticked higher on unconfirmed market chatter related to a potential combination with Gilead Sciences (NASDAQ: GILD).
Update:
Today's rumor may have roots in a research note by analyst... More
Biopharma M&A Wave to Continue, Piper Jaffray Says (GILD) (BIIB) (AMGN) (AGN) (ABBV)
September 18, 2015 8:14 AM EDTAnalysts at Piper Jaffray said the M&A wave in Biopharma is not over yet and they see a number of big players making deals over the near-term.
"With debt still easily accessible, balances sheets generally strong and payor consolidation creating pricing and growth pressures, the field remains ripe for additional activity," Piper Jaffray analysts said.
For potential biotech mergers, the analysts note most investors expect Gilead Sciences (NASDAQ: GILD) to be acquisitive and increasingly hope Biogen (NASDAQ: BIIB) will be too. They also think Amgen... More
